These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-002183-18 ESOPE (QLK3-2002-02003) European Standard Operating Procedures for Electrochemotherapy and Electrogenetherapy not-yet-due
Listed as ongoing, but also has a completion date 2006-001065-41 Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors 2009-04-20 bad-data
Ongoing 2006-001067-39 Etude de phase II de l'association 5-fluoro-uracile - acide folinique (schéma LV5FU2 simplifié) et cetuximab en intraveineux avec une chimiothérapie intra-artérielle hépatique par Oxaliplatine dans le... not-yet-due
Exempt 2007-000527-18 Monocentric, open label, uncontrolled phase I-II study to evaluate the safety and the maximum tolerated dose of sorafenib given daily in combination with temozolomide (extended schedule) in patients w... not-yet-due
Listed as ongoing, but also has a completion date 2007-001200-20 A multicenter randomized phase II Trial assessing the activity of Gemcitabine - Oxaliplatin chemotherapy alone or in combination with Cetuximab in patients with advanced biliary cancer 2010-07-27 bad-data
Listed as ongoing, but also has a completion date 2008-001436-12 Estudio Fase II no aleatorizado de tratamiento con Temozolamida combinada con Topotecan para neuroblastoma y otros tumores sólidos pediátricos en situación de recaída o progresión. "Phase 2 single-arm... 2011-07-04 bad-data
Ongoing 2008-002159-25 Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement not-yet-due
Ongoing 2008-007412-15 Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine gyn... not-yet-due
Not reported 2009-012430-70 Etude de phase II multicentrique étudiant l’efficacité de la doxorubicine associée à de la trabectedine (Yondelis) en première ligne dans le traitement des patients présentant un léiomyosarcome métas... 2016-10-12 due-trials
Ongoing 2009-015598-11 Essai de phase III multicentrique comparant la surveillance simple (standard) à la laparotomie exploratrice plus chimio-hyperthermie intrapéritonéale (CHIP), chez des patients atteints d’un cancer col... not-yet-due
Not reported 2009-017000-83 Essai de phase II évaluant l’effet curatif de la pravastatine chez des patients présentant une fibrose cutanée et sous-cutanée radio-induite établie 2018-04-18 due-trials
Ongoing 2009-017047-34 Essai de phase 2-3 randomisé, comparant deux modalités de réirradiation après chirurgie en territoire irradié des carcinomes des voies aéro-digestives supérieures : - radiothérapie monofractionnée av... not-yet-due
Ongoing 2010-019224-31 INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS not-yet-due
Ongoing 2010-024621-20 First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma not-yet-due
Other 2012-003005-10 PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA not-yet-due
Exempt 2012-004842-14 PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA not-yet-due
Ongoing 2013-000286-36 A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors not-yet-due
Ongoing 2014-001929-32 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication not-yet-due
Ongoing 2014-005586-75 A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer not-yet-due
Other 2015-003130-27 An international multicenter phase II randomized trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemoth... not-yet-due
Ongoing 2015-005464-42 A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours not-yet-due
Exempt 2016-000133-40 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors not-yet-due
Ongoing 2016-002186-56 Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in patien... not-yet-due
Ongoing 2017-000742-21 Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RA... not-yet-due
Ongoing 2017-001277-17 Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and... not-yet-due
Ongoing 2017-001606-14 A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer not-yet-due
Ongoing 2017-003622-33 Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer not-yet-due
Ongoing 2018-001447-31 Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolida... not-yet-due
Ongoing 2018-001744-62 A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-d... not-yet-due
Exempt 2018-002688-24 Phase I-II study of nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma not-yet-due
Ongoing 2018-003115-21 A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors not-yet-due